$IVVD

@adamfeuersteinAug 28, 2025 · 1:01 PM

In this week's Biotech Scorecard newsletter: The case for Invivyd $IVVD and why the RFK Jr. anti-Covid vax agenda is a boost for the company's monoclonal antibody approach to Covid prevention. I spoke with Invivyd Chairman Marc Elia. Also interesting: The FDA's post-approval study requirements for covid vaccines ( $PFE $MRNA etc) are more onerous than the study parameters suggested to Invivyd to support filing and potential approval of VYD2311. Kinda makes you go, hmmmm.... Read the online version of the newsletter at link below.

@adamfeuersteinAug 28, 2025 · 10:55 AM

@lilienfeld1 Incorrect. The proposed indication that $IVVD is seeking is for pre-exposure protection from Covid. That's also the current EUA designation for Pemgarda.

@adamfeuersteinAug 26, 2025 · 10:21 AM

Tweet below from February. $IVVD garnering attention again as potential alternative to Covid vaccines in the current anti-vaccine political climate. Eyes on last Friday's $58M raise led by RA Cap and Janus.